稳心颗粒联合美托洛尔治疗心律失常临床观察

目的探讨稳心颗粒联合美托洛尔治疗心律失常临床效果及安全性。方法回顾性分析心律失常患者56例的临床资料,随机分成对照组和治疗组,各28例,对照组予以酒石酸美托洛尔25 mg,2次/d;治疗组在对照组基础上予以稳心颗粒9 g,3次/d,温水冲服;2组疗程均为4周。比较2组治疗后临床疗效及不良反应发生率。结果治疗4周后治疗组总有效率89.3%明显优于对照组的75.0%,差异有统计学意义(P<0.05);治疗4周后治疗组心电图及动态心电图改善总有效率82.1%明显优于对照组的67.9%(P<0.05);2组不良反应发生率比较差异无统计学意义。结论稳心颗粒联合美托洛尔可以有效改善心律失常患者的临床症状,且不增加不良反应发生率,安全可靠。

Objective To study the metacentric granule combined with metoprolol arrhythmia treatment, efficacy and safety. Methods A retrospective analyzed the clinical data of 56 patients with arrhythrnia, 28 cases randomly divided into control group and treatment group, control group to be tartrate metoprolol 25 mg, 2 times/d; Treatment group in the control group on the basis of metacentric particles 9 g, 3 times/d, warm water a blunt; Two groups of a course of 4 weeks. Compare two groups of clinical curative effect and the incidence of adverse reactions after treatment. Results After 4 weeks of treatment, the treatment group total 89.3% efficiency was obviously better than that of the control group of 75% （P〈 0.05）, the difference was significant; after 4 weeks of treatment, the treatment group of ECG and Holter improve the total efficiency was 82.1% was significantly better than the control group of 67.9% （P〈0.05）, the difference is significant; two groups of incidence of adverse reactions compared, the difference was not significant. Conclusion Metacentric particles joint metoprolol can improve the clinical symptoms in patients with arrhythmia, and does not increase the incidence of adverse reactions, safe and reliable.